Epic Sciences raises $52M Series E round to advance liquid biopsy diagnostics
The San Diego-based firm plans to integrate its "No Cell Left Behind" platform with electronic medical records and big data analytics.
Biopharma just can’t get enough of Epic Sciences
Epic Sciences has to be one of the coolest kids on the biopharma block, with a new $40 million Series D financing round and a whopping 42 industry partnerships built around its novel liquid biopsy platform. For a team of just 70, the San Diego startup is doing pretty well.
With the Rise of AI, What IP Disputes in Healthcare Are Likely to Emerge?
Munck Wilson Mandala Partner Greg Howison shared his perspective on some of the legal ramifications around AI, IP, connected devices and the data they generate, in response to emailed questions.
New blood test from Epic Sciences matches patients with PARP inhibitors
Inhibiting PARP in HRD cancer cells generates more damage than the cells can withstand, ultimately killing them. The trick is identifying which patients have HRD cells and will benefit from these drugs.
Epic Sciences raises $30M for “no cell left behind” test that analyzes circulating tumor cells
With a simple blood test, Epic Sciences can help physicians monitor the condition and severity of a cancer patient’s cancer by analyzing the intricacies of his or her circulating tumor cells. The San Diego company just raised $30 million in a Series C round to commercialize what CEO Murali Prahalad calls its “no cell left behind” diagnostic […]